Thymosin Alpha-1 Chemical

File 07 - the source list

Thymosin Alpha-1 References

Every claim on this site maps to one of these sources. DOIs and PubMed identifiers included.

Back to the evidence logRead the effects page

How to read this list

These are the primary sources behind every numbered claim on the site, from the 1977 structural characterization to the 2025 phase-3 sepsis trial. Where a result is null or marginal, the summary on the relevant page says so - the citation does not change that. The list runs heavily toward randomized trials and comprehensive reviews; it leans, as the field does, on hepatitis, sepsis, COVID-19, and immune-reconstitution research. Foreign brand names are omitted on purpose; the generic name is thymalfasin throughout. Full numbered entries with DOIs and PubMed links are below.

  1. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-729. ↗
  2. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. ↗
  3. Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. ↗
  4. Billich A. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):886-889. ↗
  5. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. ↗
  6. Dominari A, Hathaway III D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. ↗
  7. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019;9:873. ↗
  8. Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepat. 2012;19 Suppl 1:52-59. ↗
  9. Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024;30(2):8-15. ↗
  10. Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin α1 levels in patients with chronic inflammatory autoimmune diseases. Clin Exp Immunol. 2016;186(1):39-45. ↗
  11. Kim BH, Lee YJ, Kim W, et al. Efficacy of thymosin alpha-1 plus peginterferon alfa-2a combination therapy compared with peginterferon alfa-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. 2012;47(8-9):1048-1055. ↗
  12. Gao D, Zhang X, Zhang J, et al. Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization. Arch Pharm Res. 2008;31(11):1471-1476. ↗
  13. Zhu Y, Lu Y, Zhong YQ. [Preparation and properties of Talpha1 loaded injectable sustained release microspheres]. Yao Xue Xue Bao. 2007;42(2):211-215. ↗
  14. Li Y, Chen H, Li X, et al. A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin alpha 1. J Intensive Care Med. 2009;24(1):47-53. ↗